Recently, we reported that a novel RNAi therapeutic platform against RPN2 demonstrated an efficient inhibition of lung tumor growth [10], but we have not yet revealed the molecular functions and clinical relevance of RPN2 in lung cancer. The gene discussed is RPN2; the disease is lung carcinoma.